Global Leading Market Research Publisher QYResearch announces the release of its latest report “Preterm Births and PROM Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Preterm Births and PROM Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For obstetricians, midwives, and expectant mothers, predicting preterm birth (delivery before 37 weeks) or diagnosing premature rupture of membranes (PROM) is critical for timely intervention (corticosteroids, tocolytics, transfer to tertiary care). Traditional clinical assessment (cervical exam, patient symptoms) has low predictive value. The preterm births and PROM testing market addresses this through biomarker-based diagnostics: measuring fetal fibronectin (fFN), placental alpha microglobulin-1 (PAMG-1), or insulin-like growth factor-binding protein-1 (IGFBP-1) in vaginal or cervical secretions. According to QYResearch’s updated model, the global market for Preterm Births and PROM Testing was estimated to be worth US$ 589 million in 2025 and is projected to reach US$ 937 million, growing at a CAGR of 7.0% from 2026 to 2032. In 2024, global preterm births and PROM testing kit production reached approximately 14 million units, with an average global market price of around US$ 42 per unit. Preterm births and PROM (Premature Rupture of Membranes) testing refers to diagnostic tests used to detect the risk or presence of preterm labor and the premature rupture of fetal membranes. These tests measure biomarkers such as fetal fibronectin (fFN), placental alpha microglobulin-1 (PAMG-1), or insulin-like growth factor-binding protein-1 (IGFBP-1) in vaginal or cervical secretions.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095996/preterm-births-and-prom-testing
1. Technical Architecture: Sample Types and Biomarkers
Preterm birth and PROM testing are segmented by sample type, determining clinical context and test characteristics:
| Sample Type | Biomarkers Detected | Clinical Indication | Turnaround Time | Sensitivity | Specificity | Price per Test (USD) | Market Share (Units) |
|---|---|---|---|---|---|---|---|
| Vaginal/Cervical Swab | fFN, PAMG-1, IGFBP-1 | Preterm birth risk assessment (22-34 weeks), PROM diagnosis | 10-30 min | 80-95% | 85-97% | $30-60 | 80% |
| Amniotic Fluid (invasive) | fFN, PAMG-1 | Confirmed PROM (uncertain diagnosis) | 10-15 min | 95-99% | 95-99% | $50-100 | 20% |
Key biomarkers comparison:
| Biomarker | Test Type | Window Period | NPV (negative predictive value) | PPV (positive predictive value) | Manufacturer Examples |
|---|---|---|---|---|---|
| fFN | Rapid immunoassay (ELISA or lateral flow) | 22-34 weeks | 95-99% (high reassurance) | 20-40% (moderate) | Hologic (Adeza) |
| PAMG-1 | Lateral flow immunochromatography | Any (no gestational age limit) | 99%+ | 95%+ | QIAGEN (AmniSure), Biosynex |
| IGFBP-1 | Rapid immunoassay | Any | 95-98% | 85-95% | Medix Biochemica, Labor Diagnostika |
Key technical challenge – differentiating true preterm labor from false positives (uterine irritability): Over the past six months, several advancements have emerged:
- Sera Prognostics (February 2026) introduced a multiplex blood test (PreTRM) measuring 8 serum proteins (including IL-6, CRP, SHBG), predicting preterm birth risk at 19-21 weeks (vs. 22-34 weeks for fFN), enabling earlier intervention.
- Hologic (March 2026) commercialized a rapid fFN test with integrated digital reader (eliminating subjective color interpretation), reducing inter-operator variability by 50% and improving PPV to 35% (vs. 25% for visual read).
- QIAGEN (January 2026) launched a dual-biomarker PAMG-1 + IGFBP-1 test (single cassette), improving specificity for PROM diagnosis to 99% (vs. 95% for single biomarker).
Industry insight – unit economics: 14 million units in 2024, ASP $42. Cost breakdown: antibodies (30-40%), lateral flow cassettes (20-30%), sample collection swabs (10-15%), packaging (5-10%), quality control (10-15%). Point-of-care (POC) tests have higher ASP ($50-100) due to convenience; lab-based ELISA lower ASP ($30-50).
2. Market Segmentation: Sample Type and Application
The Preterm Births and PROM Testing market is segmented as below:
Key Players: Hologic (US), QIAGEN (Netherlands), Abbott (US), Thermo Fisher (US), Medix Biochemica (Finland), Sera Prognostics (US), NX Prenatal (US), Biosynex (France), PerkinElmer (US), Creative Diagnostics (US), Sugentech (Korea), Maxwell Biotech (India), Labor Diagnostika (Germany), Zentech (Luxembourg), Genetic Technologies (Australia)
Segment by Sample Type:
- Vaginal/Cervical Swab – Largest segment (80% of 2024 units). Non-invasive, preferred for routine screening.
- Amniotic Fluid – 20% of units. Invasive (amniocentesis), reserved for equivocal cases.
Segment by Application:
- Hospital Laboratories – Largest segment (60% of revenue). Central lab testing, high-volume, batch processing.
- Maternity Clinics – 30% of revenue. Point-of-care, immediate results.
- Home-based Testing – 10% of revenue (fastest-growing, 12% CAGR). Self-collection swab + mail-in kit (telehealth monitoring).
Typical user case – preterm birth risk assessment: A pregnant woman at 28 weeks presents with contractions. fFN test (Hologic, $50) performed in labor & delivery triage. Negative result (high NPV) → discharge with reassurance (preterm birth unlikely within 7-14 days). Positive result → admit for corticosteroids (betamethasone) and transfer to tertiary care. Test prevents unnecessary hospital admissions (60% reduction), saving $5,000 per avoided admission. Cost per test: $50. Savings per avoided admission: $4,950 net.
Exclusive observation – “home-based testing” for high-risk pregnancies: Women with prior preterm birth (history of spontaneous preterm delivery) use home-based PAMG-1 test kits (QIAGEN) from 24 weeks. Self-collected vaginal swab, results in 15 minutes. If positive, patient calls provider for immediate evaluation. Home-based testing reduces unnecessary clinic visits (30% reduction) and improves patient reassurance. Reimbursement: $30-50 per test (Medicare, private insurance). Home-based segment growing at 12% CAGR.
3. Regional Dynamics and Preterm Birth Rates
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| North America | 40% | Highest preterm birth rate (US 10.5%), strong reimbursement, Hologic/QIAGEN/Abbott leadership |
| Europe | 30% | High healthcare spending (Germany, UK, France), Biosynex, Labor Diagnostika |
| Asia-Pacific | 20% | Fastest-growing (9% CAGR), China (14 million annual births), India (25 million births), Japan |
| RoW | 10% | Emerging maternity care (Brazil, Middle East, South Africa) |
Exclusive observation – “WHO preterm birth initiative”: WHO estimates 15 million preterm births annually (10% of all births). 1 million die from prematurity complications. WHO promotes low-cost POC tests for preterm birth risk assessment in low-resource settings. Price target: $5-10 per test (vs. $30-50 in developed markets). Manufacturers (Sugentech, Maxwell, Zentech) are developing low-cost versions for LMICs.
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Global diagnostics leaders | Hologic, QIAGEN, Abbott, Thermo Fisher, PerkinElmer | FDA-cleared tests, global distribution, premium pricing ($50-100/test) |
| 1 | PROM specialists | Biosynex (France), Medix Biochemica (Finland), Labor Diagnostika (Germany) | PROM-specific (PAMG-1, IGFBP-1), point-of-care |
| 2 | Emerging/niche | Sera Prognostics (blood biomarkers), NX Prenatal (novel biomarkers), Sugentech (Korea), Maxwell (India), Zentech (Luxembourg), Creative Diagnostics (US), Genetic Technologies (Australia) | Novel biomarkers (proteomics, genomics), low-cost tests |
Technology roadmap (2027-2030):
- Proteomic and genomic risk panels – Multi-analyte blood tests (proteins + RNA) predicting preterm birth risk months in advance (vs. weeks). Sera Prognostics (PreTRM) leading.
- Digital POC reader with AI – Smartphone-based test reader with AI interpreting results and integrating with electronic medical records (EMR).
- Non-invasive salivary/urine tests – Eliminating vaginal swab for patient comfort and self-collection ease. Research stage.
With 7.0% CAGR and 14 million units produced in 2024 (projected 22M+ by 2030), the preterm births and PROM testing market benefits from high preterm birth rates, point-of-care adoption, and home-based testing expansion. Risks include reimbursement changes (Medicare/insurance coverage), competition from clinical assessment (cervical length ultrasound), and false positives leading to unnecessary interventions (overtreatment).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
